---
id: leishmaniasis_097
category: organisms
tags: [leishmaniasis, Leishmania, sandfly, visceral-leishmaniasis, cutaneous-leishmaniasis]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Leishmaniasis

**Q:** What are the three clinical forms of leishmaniasis (visceral, cutaneous, mucosal), their geographic distribution, and treatment approaches?

**A:**

## OVERVIEW

**Organism:** *Leishmania* species (intracellular protozoan parasites)

**Transmission:**
- **Sandfly bite** (*Phlebotomus* spp. in Old World, *Lutzomyia* spp. in New World)
- **Female sandflies** are vectors

**Geographic Distribution:**
- **88 countries:** South/Central America, Africa, Asia, Southern Europe (Mediterranean)
- **~1.7 billion people at risk** (1/4 of world population)

**Epidemiology:**
- **~1 million new cases/year** (cutaneous)
- **50,000-90,000 new cases/year** (visceral)
- **Endemic regions:** India, Bangladesh, Brazil, East Africa (Sudan, Ethiopia, Kenya)

---

## THREE CLINICAL FORMS

| **Form** | **Species** | **Geographic Distribution** | **Key Features** |
|----------|-------------|----------------------------|------------------|
| **Visceral (Kala-azar)** | ***L. donovani*** (Old World)<br>***L. infantum/chagasi*** (New World, Mediterranean) | India, Bangladesh, East Africa, Mediterranean, Brazil | **Fever, splenomegaly, pancytopenia** (fatal if untreated) |
| **Cutaneous** | ***L. major, L. tropica*** (Old World)<br>***L. braziliensis, L. mexicana*** (New World) | Middle East, Central/South America, Mediterranean | **Painless ulcer** with raised border |
| **Mucosal (Espundia)** | ***L. braziliensis*** (New World) | Latin America (Peru, Bolivia, Brazil) | **Destructive mucosal lesions** (nose, mouth) |

**Key Point:** **Visceral = fatal if untreated**, **Cutaneous = self-limited**, **Mucosal = disfiguring**

---

## 1. VISCERAL LEISHMANIASIS (KALA-AZAR)

**Definition:** Systemic infection with dissemination to reticuloendothelial system

**Causative Organisms:**
- ***L. donovani*** (India, Bangladesh, East Africa)
- ***L. infantum*** (Mediterranean, Middle East)
- ***L. chagasi*** (Latin America - Brazil, Venezuela)

---

### **Clinical Features:**

**Classic Triad:**
- **Fever** (remittent, undulant - "double rise" in afternoon/evening)
- **Massive splenomegaly** (extends to pelvis)
- **Pancytopenia** (anemia, leukopenia, thrombocytopenia)

**Other Findings:**
- **Hepatomegaly** (less prominent than spleen)
- **Weight loss, cachexia**
- **Hyperpigmentation** ("kala-azar" = black fever/disease in Hindi)
- **Lymphadenopathy** (Africa - Sudan)

**Incubation:** 2-6 months (range: weeks to years)

**Mortality:** **>95% if untreated**

---

### **Diagnosis:**

**Laboratory Findings:**
- **Pancytopenia** (anemia, leukopenia, thrombocytopenia)
- **Hypergammaglobulinemia** (polyclonal IgG)
- **Hypoalbuminemia**
- **↑ Alkaline phosphatase**

**Diagnostic Tests:**

| **Test** | **Sensitivity** | **Specimen** | **Notes** |
|----------|-----------------|--------------|-----------|
| **Bone marrow aspirate** (microscopy + culture) | **60-85%** | Bone marrow | Gold standard (visualize amastigotes) |
| **Splenic aspirate** | **>95%** | Spleen | **Highest yield** but risk of bleeding |
| **rK39 rapid diagnostic test (RDT)** | **85-95%** | Serum | **Best for Indian subcontinent**, lower sensitivity in Africa |
| **PCR** | **>90%** | Blood, bone marrow | High sensitivity/specificity |

**Key Point:** **Splenic aspirate = highest yield** (but bleeding risk), **rK39 RDT = rapid, non-invasive** (best in India)

---

### **Treatment:**

#### **Immunocompetent Patients:**

**First-Line (FDA-Approved):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Liposomal amphotericin B (L-AmB)** | **3 mg/kg IV daily** on days 1-5, 14, 21<br>**(Total dose: 21 mg/kg)** | **7 doses over 21 days** |

**Alternative (If L-AmB Unavailable):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Miltefosine** (oral) | **2.5 mg/kg PO daily** (max 150 mg/day) | **28 days** |
| **OR Paromomycin** (IM) | **15 mg/kg IM daily** | **21 days** |
| **OR Pentavalent antimonials** (Sodium stibogluconate) | **20 mg/kg IV/IM daily** | **28-30 days** |

**Key Point:** **Liposomal amphotericin B = first-line** (FDA-approved, short course)

---

#### **HIV-Coinfected Patients:**

**Treatment:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Liposomal amphotericin B** | **4 mg/kg IV daily** on days 1-5, 10, 17, 24, 31, 38<br>**(Total dose: 40 mg/kg)** | **10 doses over 38 days** |

**Alternative (Combination - Per WHO 2022 Guidelines):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Liposomal amphotericin B** | **30 mg/kg total dose** (divided over 6-10 days) | **~10 days** |
| **PLUS Miltefosine** | **100 mg PO daily** | **28 days** |

**Efficacy:**
- **Combination:** 88% cure rate
- **L-AmB monotherapy:** 55% cure rate

**Secondary Prophylaxis (HIV Patients):**
- **Liposomal amphotericin B** 4 mg/kg IV every 2-4 weeks (until CD4 >200 x 6 months on ART)
- **Alternative:** Pentamidine 4 mg/kg IV monthly OR miltefosine 50 mg PO daily

**Key Point:** **HIV patients need higher L-AmB doses** (40 mg/kg total) + **secondary prophylaxis**

---

### **Post-Kala-Azar Dermal Leishmaniasis (PKDL):**

**Definition:** Dermal manifestations after apparent cure of visceral leishmaniasis

**Clinical Features:**
- **Hypopigmented or erythematous macules/papules/nodules**
- **Face, trunk, extremities**
- **Onset:** Months to years after VL treatment

**Geographic Distribution:**
- **India:** 5-10% of VL cases (onset years after treatment)
- **Sudan/East Africa:** 50-60% of VL cases (onset weeks to months after treatment)

**Treatment:**
- **Liposomal amphotericin B** (as for VL) OR **Miltefosine** 28 days

---

## 2. CUTANEOUS LEISHMANIASIS (CL)

**Definition:** Localized skin infection (most common form)

**Causative Organisms:**

**Old World:**
- ***L. major*** (Middle East, North Africa)
- ***L. tropica*** (Middle East, Mediterranean)

**New World:**
- ***L. braziliensis*** (Latin America)
- ***L. mexicana*** (Central America, Southern US)

---

### **Clinical Features:**

**Typical Lesion:**
- **Painless papule** → **Ulcer with raised, violaceous border**
- **"Volcano sign"** (central crater with raised rim)
- **Single or multiple lesions**
- **Regional lymphadenopathy** (sporotrichoid spread)

**Incubation:** Weeks to months

**Natural History:**
- **Self-limited** (heals in 3-18 months)
- **Scar formation** (often depressed, atrophic)

**Variants:**
- **Diffuse cutaneous leishmaniasis:** Nodular lesions (anergic, poor cell-mediated immunity)
- **Leishmaniasis recidivans:** Chronic, relapsing lesions around scar

---

### **Diagnosis:**

| **Test** | **Specimen** | **Sensitivity** |
|----------|--------------|-----------------|
| **Tissue biopsy** (microscopy + culture) | Skin biopsy (ulcer edge) | 60-80% |
| **PCR** | Skin biopsy | >90% |
| **Touch prep/scraping** | Lesion scraping | 50-70% |

**Key Point:** **Biopsy ulcer edge** (highest organism load)

---

### **Treatment:**

**Indications for Treatment (Not All Require Treatment):**
- **Complex lesions:** Multiple (>4), large (>4 cm), facial, disabling
- **Risk of mucosal spread** (*L. braziliensis*)
- **Immunocompromised host**

**First-Line (FDA-Approved):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Miltefosine** (oral) | **2.5 mg/kg PO daily** (max 150 mg/day) | **28 days** |

**Alternative:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Liposomal amphotericin B** | **3 mg/kg IV daily** | **6-10 doses** (total 18-30 mg/kg) |
| **OR Pentavalent antimonials** | **20 mg/kg IV/IM daily** | **20 days** |
| **OR Pentamidine** | **2-3 mg/kg IV/IM every other day** | **4-7 doses** |

**Local Therapy (Simple, Non-Facial Lesions):**
- **Intralesional pentavalent antimonials** (0.2-2 mL per lesion every 2-3 days x 3-8 doses)
- **Cryotherapy** (liquid nitrogen)
- **Topical paromomycin** (15% + 12% methylbenzethonium chloride in white soft paraffin)

**Key Point:** **Miltefosine = oral, FDA-approved** for cutaneous leishmaniasis

---

## 3. MUCOSAL LEISHMANIASIS (ESPUNDIA)

**Definition:** Destructive mucosal lesions (nose, mouth, pharynx)

**Causative Organism:**
- ***L. braziliensis*** (Latin America - Peru, Bolivia, Brazil)

**Pathophysiology:**
- **Hematogenous or lymphatic spread** from cutaneous lesion (months to years later)
- **1-10% of *L. braziliensis* cutaneous cases** progress to mucosal

---

### **Clinical Features:**

**Sites:**
- **Nasal mucosa** (most common) → nasal stuffiness, epistaxis
- **Oral mucosa, pharynx, larynx**

**Progression:**
- **Ulceration, perforation** of nasal septum
- **Destruction of palate**
- **"Tapir nose"** (drooping nose from cartilage destruction)

**Key Point:** **Mucosal leishmaniasis = disfiguring** (requires aggressive treatment)

---

### **Treatment:**

**First-Line:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Liposomal amphotericin B** | **3 mg/kg IV daily** | **10-20 doses** (total 30-60 mg/kg) |

**Alternative:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Pentavalent antimonials** | **20 mg/kg IV/IM daily** | **28 days** |
| **PLUS Pentoxifylline** (adjunctive) | **400 mg PO TID** | **28 days** |

**Key Point:** **Mucosal leishmaniasis requires longer treatment** (higher total L-AmB dose)

---

## PREVENTION

**Vector Control:**
- **Insecticide-treated bed nets**
- **Indoor residual spraying**

**Personal Protection:**
- **DEET repellents**
- **Permethrin-treated clothing**
- **Avoid outdoor activities at dusk/dawn** (peak sandfly activity)

---

**Mnemonic: "VCM for Three Forms (Visceral, Cutaneous, Mucosal)"**
- **V**isceral = **F**atal (fever, splenomegaly, pancytopenia)
- **C**utaneous = **S**elf-limited (ulcer with raised border)
- **M**ucosal = **D**isfiguring (nasal/oral destruction)

**Mnemonic: "Kala-Azar Triad = Fever + Spleen + Pancytopenia"**
- **K**ala-azar (visceral leishmaniasis)
- **F**ever (undulant)
- **S**plenomegaly (massive)
- **P**ancytopenia

**Mnemonic: "L-AmB for Leishmania (Liposomal Amphotericin B)"**
- **L**-AmB = **L**eishmaniasis first-line
- **V**isceral: 21 mg/kg total (immunocompetent), 40 mg/kg (HIV)
- **C**utaneous: 18-30 mg/kg total
- **M**ucosal: 30-60 mg/kg total

**Clinical Pearls:**
- **Visceral leishmaniasis = fatal if untreated** (>95% mortality)
- **Classic triad:** Fever + massive splenomegaly + pancytopenia
- **rK39 RDT = rapid diagnosis** (best in Indian subcontinent, lower sensitivity in Africa)
- **Splenic aspirate = highest yield** (>95% sensitivity, but bleeding risk)
- **Liposomal amphotericin B (L-AmB) = first-line** for all forms (FDA-approved)
- **Visceral (immunocompetent):** 21 mg/kg total (days 1-5, 14, 21)
- **Visceral (HIV):** 40 mg/kg total (days 1-5, 10, 17, 24, 31, 38) + secondary prophylaxis
- **Cutaneous leishmaniasis:** Not all cases require treatment (treat if complex, facial, or *L. braziliensis*)
- **Miltefosine = oral option** (FDA-approved for cutaneous and visceral)
- **Mucosal leishmaniasis = disfiguring** (nasal septum perforation, palate destruction)
- ***L. braziliensis* → risk of mucosal spread** (treat cutaneous aggressively)
- **Post-kala-azar dermal leishmaniasis (PKDL):** Hypopigmented macules/papules after VL cure
- **Sandfly vector:** *Phlebotomus* (Old World), *Lutzomyia* (New World)

**Media:** None

**Sources:** [IDSA/ASTMH 2016 - Leishmaniasis clinical practice guidelines], [WHO 2022 - VL-HIV coinfection treatment guideline], [CDC 2024 - Leishmaniasis clinical care], [NIH/HIVMA 2024 - Leishmaniasis in HIV], [NEJM 2024 - Leishmaniasis], [PAHO 2022 - Updated treatment guidelines for the Americas]
